NCT07150299View on ClinicalTrials.gov

Myocardial Perfusion Changes Following Optimal Medical Treatment in Symptomatic Hypertrophic Cardiomyopathy

RecruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

September 5, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

September 30, 2027

Conditions

Hypertrophic Obstructive Cardiomyopathy \(HOCM\)

Interventions

DRUG

Mavacamten in clinical routine use

Clinical observation of mavacamten use

Trial Locations (1)

2362

RECRUITING

Medical University of Vienna, Vienna

All Listed Sponsors

lead

Medical University of Vienna

OTHER

NCT07150299 - Myocardial Perfusion Changes Following Optimal Medical Treatment in Symptomatic Hypertrophic Cardiomyopathy | Biotech Hunter | Biotech Hunter